EP4110396A1 — Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia
Assigned to Universiteit Maastricht · Expires 2023-01-04 · 3y expired
What this patent protects
The present invention relates to a therapeutic combination comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist. More specifically, the invention relates to said therapeuti…
USPTO Abstract
The present invention relates to a therapeutic combination comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist. More specifically, the invention relates to said therapeutic combination for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia- reperfusion injury. The invention also relates to a pharmaceutical composition comprising two or three of at least one NADPH oxidase inhibitor, at least one nitric oxide synthase inhibitor and at least one soluble guanylate cyclase agonist, and to said pharmaceutical composition for use in the prevention or treatment of brain ischemia or for use in the prevention or treatment of ischemia-reperfusion injury.
Drugs covered by this patent
- Verquvo (VERICIGUAT) · Merck & Co.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.